
Emerging B-Cell Therapies and Real-World Evidence in IgAN
Pipeline B-cell agents differ in design, dosing interval, and populations studied. Dr. Geara explains why real-world evidence matters for patients who were excluded from trials, and the panel names the gaps they most want filled.
Episodes in this series

Dr. Wadhwani asks Dr. Cheung which features could set emerging B-cell modulators apart from approved therapies, including povetacicept and telitacicept. Dr. Cheung says povetacicept uses an engineered TACI receptor that binds both APRIL and BAFF more strongly, making it a potent agent given once every four weeks. Data at Kidney Week showed roughly 50 percent proteinuria reduction and about a 77 percent reduction in galactose-deficient IgA1. Two-year eGFR data and safety data are still needed.
Dr. Cheung also describes results from a Chinese population with well-preserved kidney function, with eGFR in the mid-70s, in whom kidney function stabilized over two years. Testing in other populations would show whether those findings reproduce more broadly. Dr. Wadhwani welcomes the consistency across the class and the prospect of more options for patients worldwide.
The conversation moves to real-world evidence. Dr. Geara says it matters first because it affirms trial results. Trial participants represent a small share of the IgAN population, and patients with very high proteinuria, advanced chronic kidney disease, IgA vasculitis, or secondary IgA disease were often excluded. Real-world data begin to include them. Safety is the second reason. Real patients more often have diabetes and other comorbidities, which could bring more adverse effects.
Dr. Wadhwani asks which gaps would most change practice. Dr. Cheung points to combinations of different classes, which clinicians are already using, and calls for systematic capture of their benefits against added side effects. Long-term kidney outcomes and sequencing were also named as priorities. Dr. Wadhwani adds that she looks forward to seeing more of this real-world data published.
In "The Future of IgAN Care: Personalized Goals and Practice-Changing Steps," the panel will look ahead at how the treatment algorithm may evolve, how to define success, and what each panelist would change tomorrow.
Related to this article








